Clinical impact of drug-eluting Stents in changing referral practices for coronary surgical revascularization in a tertiary care center

被引:35
作者
Ferreira, AC
Peter, AA
Salerno, TA
Bolooki, H
de Marchena, E
机构
[1] Univ Miami, Sch Med, Dept Med, Div Cardiol, Miami, FL USA
[2] Univ Miami, Sch Med, Dept Surg, Div Cardiothorac Surg, Miami, FL USA
关键词
D O I
10.1016/S0003-4975(02)04367-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The long-term benefits of angioplasty are limited by the occurrence of restenosis. Drug-eluting stents with a projected restenosis rate of close to 0% are soon to become available. The short- and long-term consequences of this advance to the cardiac surgical volume remain unclear. Methods. A total of 196 consecutive coronary angiograms and medical records of patients referred for coronary bypass surgery were reviewed. Considering the hypothetical premise of having drug-eluting stents with a near zero restenosis rate, we reviewed each case to determine if surgical revascularization was still the preferred option for revascularization. Results. The mean age was 60 (+/-10.6) years. Seventy-two percent of patients were male. Considering the availability of drug-eluting stents 154 (79%) would still have been sent to surgery, representing a 21% decrease in the number of surgical revascularizations. Angiographic characteristics predicting coronary bypass revascularization were the presence of chronic total occlusion (odds ratio [OR]: 9.1; confidence interval [CI]: 2.1 to 39), left main coronary artery stenosis (OR: 9.6; Cl: 1.27 to 73), and need for valvular surgery (OR: 7.38; Cl: 1.3 to 157). The most common predictors of a change in clinical management from surgical to percutaneous revascularization if drug-eluting stents were available were diffuse coronary narrowing (OR: 15.78). restenotic lesions (OR: 27.86), and small coronary arteries (OR: 26). Conclusions. Drug-eluting stents may have a significant impact on cardiac surgery volume (approximately a 21% decrease in our center). It may also direct patients with small vessels, diffuse narrowing, or restenotic lesions and diabetic patients to percutaneous therapy. (C) 2003 by The Society of Thoracic Surgeons..
引用
收藏
页码:485 / 489
页数:5
相关论文
共 31 条
[1]   Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients - Insights from the Arterial Revascularization Therapy Study (ARTS) trial [J].
Abizaid, A ;
Costa, MA ;
Centemero, M ;
Abizaid, AS ;
Legrand, VMG ;
Limet, RV ;
Schuler, G ;
Mohr, FW ;
Lindeboom, W ;
Sousa, AGMR ;
Sousa, JE ;
van Hout, B ;
Hugenholtz, PG ;
Unger, F ;
Serruys, PW .
CIRCULATION, 2001, 104 (05) :533-538
[2]  
Alderman EL, 1996, NEW ENGL J MED, V335, P217
[3]   The sirolimus coated stent: will the Achilles heel of interventional cardiology finally be cured? [J].
Beyar, R ;
Roguin, A .
EUROPEAN HEART JOURNAL, 2001, 22 (22) :2054-2057
[4]   Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin [J].
Braun-Dullaeus, RC ;
Mann, MJ ;
Seay, U ;
Zhang, LN ;
von der Leyen, HE ;
Morris, RE ;
Dzau, VJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (07) :1152-1158
[5]   INTRACORONARY HEPARIN DELIVERY IN HUMANS - ACUTE FEASIBILITY AND LONG-TERM RESULTS [J].
CAMENZIND, E ;
KINT, PP ;
DIMARIO, C ;
LIGTHART, J ;
VANDERGIESSEN, W ;
BOERSMA, E ;
SERRUYS, PW .
CIRCULATION, 1995, 92 (09) :2463-2472
[6]   Downregulation of cyclin-dependent kinase 2 activity and cyclin a promoter activity in vascular smooth muscle cells by p27(KIP1), inhibitor of neointima formation in the rat carotid artery [J].
Chen, DH ;
Krasinski, K ;
Chen, DF ;
Sylvester, A ;
Chen, J ;
Nisen, PD ;
Andres, V .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (10) :2334-2341
[7]   Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months [J].
Drachman, DE ;
Edelman, ER ;
Seifert, P ;
Groothuis, AR ;
Bornstein, DA ;
Kamath, KR ;
Palasis, M ;
Yang, DC ;
Nott, SH ;
Rogers, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) :2325-2332
[8]   A RANDOMIZED COMPARISON OF CORONARY-STENT PLACEMENT AND BALLOON ANGIOPLASTY IN THE TREATMENT OF CORONARY-ARTERY DISEASE [J].
FISCHMAN, DL ;
LEON, MB ;
BAIM, DS ;
SCHATZ, RA ;
SAVAGE, MP ;
PENN, I ;
DETRE, K ;
VELTRI, L ;
RICCI, D ;
NOBUYOSHI, M ;
CLEMAN, M ;
HEUSER, R ;
ALMOND, D ;
TEIRSTEIN, PS ;
FISH, RD ;
COLOMBO, A ;
BRINKER, J ;
MOSES, J ;
SHAKNOVICH, A ;
HIRSHFELD, J ;
BAILEY, S ;
ELLIS, S ;
RAKE, R ;
GOLDBERG, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (08) :496-501
[9]   The use of 188Re to treat in-stent re-stenosis of coronary arteries [J].
Fox R.A. ;
Barker P. ;
Guy D. ;
Smart G. ;
Henson P.W. ;
Mews G.C. ;
Gibbons F. .
Australasian Physics & Engineering Sciences in Medicine, 2001, 24 (3) :160-165
[10]   The rapamycin-sensitive signal transduction pathway as a target for cancer therapy [J].
Hidalgo, M ;
Rowinsky, EK .
ONCOGENE, 2000, 19 (56) :6680-6686